Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the inflammation segment. It markets medicines in the areas of orphan diseases, rheumatology and inflammation division. The majority of revenue is generated in the United States.
| Website: | www.horizonpharma.com |
| Email: | investor-relations@horizonpharma.com |
| Main Phone: | +353 17722100 |
| Address: | 1 Burlington Road |
| Address 2: | Connaught House, 1st Floor |
| City / Town: | Dublin 4 |
| Country: | IE |
| Postal Code: | D04 C5Y6 |
| Exchange: | NGS |
| CEO: | Timothy P. Walbert |
| Employees: | 1225 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Four stocks positioned right at key technical breakout points.
Picking small-cap health care stocks can be a pretty iffy endeavor. With the science unclear until the results of various clinical trials, it’s extremely difficult to get a reliable
It’s been a tough year for small-cap companies thus far in 2014. The recent market pullback hit growth companies hard as investors appeared to be interested in reducing the risk profile of
Diversified manufacturer Honeywell Intl Inc. (HON) reported on Friday that its profits in the first quarter grew by 17 percent even though sales were essentially flat as its cost-cutting efforts
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the inflammation segment. It markets medicines in the areas of orphan diseases, rheumatology and inflammation division. The majority of revenue is generated in the United States.
| Website: | www.horizonpharma.com |
| Email: | investor-relations@horizonpharma.com |
| Main Phone: | +353 17722100 |
| Address: | 1 Burlington Road |
| Address 2: | Connaught House, 1st Floor |
| City / Town: | Dublin 4 |
| Country: | IE |
| Postal Code: | D04 C5Y6 |
| Exchange: | NGS |
| CEO: | Timothy P. Walbert |
| Employees: | 1225 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Four stocks positioned right at key technical breakout points.
Picking small-cap health care stocks can be a pretty iffy endeavor. With the science unclear until the results of various clinical trials, it’s extremely difficult to get a reliable
It’s been a tough year for small-cap companies thus far in 2014. The recent market pullback hit growth companies hard as investors appeared to be interested in reducing the risk profile of
Diversified manufacturer Honeywell Intl Inc. (HON) reported on Friday that its profits in the first quarter grew by 17 percent even though sales were essentially flat as its cost-cutting efforts
| Last Price 74.93 | Change $ -2.79 | Change % -3.59 | Tick N/A |
| Bid 75.00 | Bid Size 800.00 | Ask 78.41 | Ask Size 900.00 |
| Open 76.81 | High 77.94 | Low 73.75 | Prev Close 77.72 |
| Last Trade | Volume 2.9 mi | 52 Wk Hi 86.67 | 52 Wk Low 23.81 |
| Market Cap 16.5 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 220,346,699.00 | EPS (TTM) 2.61 | PE Ratio 29.60 | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 36 | 64 |
| Number of Buys | 18 | 32 |
| Number of Sells | 18 | 32 |
| Net Activity | 242822 | 343770 |
| Last 10 Buys | Shares |
|---|---|
| Michael G. Grey | 1,000 |
| H. Thomas Watkins | 1,000 |
| H. Thomas Watkins | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Brian K. Beeler | 1,000 |
| Brian K. Beeler | 1,000 |
| Timothy P. Walbert | 1,000 |
| Brian K. Beeler | 1,000 |
| Robert F. Carey | 1,000 |
| Robert F. Carey | 1,000 |
| Jeffrey W. Sherman | 1,000 |
| Virinder Nohria | 1,000 |
| Jeffrey W. Sherman | 1,000 |
| Jeffrey W. Sherman | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 24 | 24 | 24 | 24 |
| Low Target Price Estimate | 16 | 16 | 16 | 16 |
| Mean Target Price Estimate | 20 | 20 | 20 | 20 |
| Standard Deviation | 3.21 | 3.21 | 3.21 | 3.21 |
| Date of Most Recent Estimate | 05/22/18 | 05/22/18 | 05/22/18 | 05/22/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| CT ORDER | 1 | 2018-05-14 | |
| S-8 | Securities offered to employees under employee benefit plans | 10 | 2018-05-11 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 112 | 2018-05-09 |
| 8-K | Report of unscheduled material events or corporate changes. | 20 | 2018-05-09 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 1 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1.29 | 1.29 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait